Among 15 analysts covering The Allstate Corporation (NYSE:ALL), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. The Allstate Corporation had 24 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Allstate Corp (NYSE:ALL) has “Buy” rating given on Friday, February 5 by Citigroup. The company was downgraded on Friday, January 6 by Credit Suisse. Citigroup upgraded Allstate Corp (NYSE:ALL) on Tuesday, December 1 to “Neutral” rating. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Tuesday, August 4 report. The rating was maintained by Compass Point on Wednesday, August 5 with “Neutral”. The firm has “Hold” rating given on Monday, August 10 by Deutsche Bank. The rating was maintained by FBR Capital on Monday, April 3 with “Mkt Perform”. As per Wednesday, August 5, the company rating was upgraded by Macquarie Research. The rating was maintained by Deutsche Bank on Thursday, August 4 with “Buy”. The stock has “Outperform” rating by Credit Suisse on Tuesday, November 3. See Allstate Corp (NYSE:ALL) latest ratings:
19/04/2017 Broker: Macquarie Research Old Rating: Outperform New Rating: Neutral New Target: $81.00 Downgrade
03/04/2017 Broker: FBR Capital Rating: Mkt Perform Old Target: $70.00 New Target: $82.00 Maintain
01/03/2017 Broker: Keefe Bruyette & Woods Old Rating: Outperform New Rating: Mkt Perform Downgrade
10/01/2017 Broker: Goldman Sachs Old Rating: Neutral New Rating: Buy Upgrade
06/01/2017 Broker: Credit Suisse Old Rating: Outperform New Rating: Neutral Downgrade
The stock of Cempra Inc (NASDAQ:CEMP) is a huge mover today! About 563,514 shares traded. Cempra Inc (NASDAQ:CEMP) has declined 84.36% since September 21, 2016 and is downtrending. It has underperformed by 94.79% the S&P500.The move comes after 5 months positive chart setup for the $208.26 million company. It was reported on Apr, 28 by Barchart.com. We have $4.33 PT which if reached, will make NASDAQ:CEMP worth $18.74 million more.
Investors sentiment increased to 0.97 in Q4 2016. Its up 0.11, from 0.86 in 2016Q3. It increased, as 45 investors sold Allstate Corp shares while 276 reduced holdings. 93 funds opened positions while 219 raised stakes. 266.79 million shares or 0.98% less from 269.42 million shares in 2016Q3 were reported. Earnest Prtnrs Lc has 202 shares. 241 were accumulated by Burt Wealth Advisors. 3,039 are held by Girard. Lenox Wealth Mngmt holds 872 shares. Live Your Vision Llc has invested 0% of its portfolio in Allstate Corp (NYSE:ALL). Bollard Ltd Company accumulated 16,602 shares. Louisiana State Employees Retirement Sys stated it has 0.09% in Allstate Corp (NYSE:ALL). 4,775 are owned by Cutter & Brokerage Inc. First Fincl Bank Na reported 14,528 shares. Braun Stacey Associates reported 137,512 shares. Fukoku Mutual Life reported 0.03% in Allstate Corp (NYSE:ALL). Tiedemann Wealth Mgmt Ltd Liability Com has 3,120 shares. Meyer Handelman reported 273,717 shares. Stearns Finance Group Inc has 0.06% invested in Allstate Corp (NYSE:ALL) for 2,952 shares. Allianz Asset Mngmt Ag owns 1.01 million shares.
About 116,699 shares traded. Allstate Corp (NYSE:ALL) has risen 19.40% since September 21, 2016 and is uptrending. It has outperformed by 8.97% the S&P500.
Since November 18, 2016, it had 0 insider buys, and 12 insider sales for $17.87 million activity. TAYLOR MARY ALICE sold $777,200 worth of Allstate Corp (NYSE:ALL) on Friday, February 3. 24,444 shares were sold by Lees Susan L, worth $1.99M on Monday, February 27. On Tuesday, January 3 Gupta Sanjay sold $2.72 million worth of Allstate Corp (NYSE:ALL) or 36,744 shares. The insider SPRIESER JUDITH A sold 8,000 shares worth $590,480. On Tuesday, December 13 Gupta Suren sold $3.37M worth of Allstate Corp (NYSE:ALL) or 46,297 shares. The insider Winter Matthew E sold $2.79 million. Another trade for 21,178 shares valued at $1.53 million was made by PILCH SAMUEL H on Monday, November 21.
The Allstate Corporation is a holding firm for Allstate Insurance Company. The company has market cap of $29.87 billion. The Company’s business is conducted principally through Allstate Insurance Company, Allstate Life Insurance Company and other subsidiaries. It has a 17.4 P/E ratio. It is engaged in the property-liability insurance business and the life insurance, retirement and investment products business.
Cempra, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $208.26 million. The Firm focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. It currently has negative earnings. The Company’s product, solithromycin , which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Since January 5, 2017, it had 0 insider buys, and 3 sales for $4.08 million activity. GOLDSTEIN DOV A MD sold $533,116 worth of stock.
Among 16 analysts covering Cempra (NASDAQ:CEMP), 2 have Buy rating, 3 Sell and 11 Hold. Therefore 13% are positive. Cempra had 32 analyst reports since July 30, 2015 according to SRatingsIntel. Needham downgraded the shares of CEMP in report on Sunday, November 13 to “Hold” rating. On Tuesday, August 2 the stock rating was maintained by Jefferies with “Buy”. The stock of Cempra Inc (NASDAQ:CEMP) has “Market Perform” rating given on Monday, November 21 by Cowen & Co. The firm has “Neutral” rating given on Friday, December 30 by TH Capital. On Friday, November 11 the stock rating was downgraded by Needham to “Hold”. The firm earned “Neutral” rating on Thursday, December 29 by Ladenburg Thalmann. The company was maintained on Thursday, July 30 by Needham. The stock of Cempra Inc (NASDAQ:CEMP) has “Mkt Perform” rating given on Tuesday, October 13 by Leerink Swann. JP Morgan downgraded the stock to “Neutral” rating in Thursday, November 3 report. Roth Capital downgraded the stock to “Neutral” rating in Friday, December 30 report.
